• Takeda broadens gene therapy scope, turns to Poseida for non-viral approach

    4 days ago - By MedCity News

    The progress of gene therapies continues to be stymied by safety risks associated with the viruses used to deliver them. Takeda Pharmaceutical is partnering with Poseida Therapeutics in a bet that the biotech's non-viral technologies could offer a safer alternative.
    Read more ...